Migraine in patients with systemic lupus erythematosus is associated with reduced cerebral grey matter volume but not with measures of glial activation or anti‐NR2 or anti‐P antibodies. (20th January 2016)

• Record Type: Journal Article
• Authors: Tjensvoll, A. B.; Lauvsnes, M. B.; Hirohata, S.; Beyer, M. K.; Greve, O. J.; Kvivik, I.; Kvaløy, J. T.; Harboe, E.; Gøransson, L. G.; Omdal, R.
• Is Part Of: European journal of neurology. Volume 23:Number 4(2016:Apr.)
• Page Start: 780
• Page End: 786
• Publication Date: 2016-01-20
• Subjects: anti‐NR2 -- anti‐P -- autoimmune disease -- headache -- migraine -- MRI -- S100B -- systemic lupus erythematosus; Neurology -- Periodicals; Nervous system -- Diseases -- Periodicals; 616.8
• DOI: 10.1111/ene.12946
• Languages: English
• ISSNs: 1351-5101

Abstract

Abstract : Background and purpose: Migraine is frequent in patients with systemic lupus erythematosus (SLE), but the pathogenesis and pathophysiology are poorly understood. Migraine is assumed to be a consequence of abnormal neuronal excitability. Based on the hypothesis that the threshold for migraine is lower in SLE patients due to cerebral disturbances, whether structural abnormalities of the brain or relevant biomarkers are associated with headaches in SLE was investigated. Methods: Sixty‐seven SLE patients and age‐ and gender‐matched healthy subjects participated. Volumes of grey matter (GM) and white matter (WM) were estimated from cerebral magnetic resonance images with SPM8 software. Anti‐NR2 and anti‐P antibodies and protein S100B were measured in cerebrospinal fluid. Results: In regression analyses, larger GM volumes in SLE patients reduced the odds for headache in general [odds ratio (OR) 0.98, P = 0.048] and for migraine in particular (OR 0.95, P = 0.004). No localized loss of GM was observed. Larger WM volumes in patients increased the odds for migraine (OR 1.04, P = 0.007). These findings could not be confirmed in healthy subjects. Neither anti‐NR2 and anti‐P antibodies nor S100B were associated with headaches in SLE patients. Conclusions: Systemic lupus erythematosus patients with migraine have a diffuse reduction in GM compared to patients without migraine. This finding was not observed in healthy subjects with migraine, and selected biomarkers did not indicate specific pathophysiological processes in the brain. These findings indicate that unknown pathogenic processes are responsible for the increased frequency of migraine in SLE patients.